A CML blast phase prognostic score separates patients into three risk groups with distinct survival. Separate AML studies identified circRNA and NFS1/GSDMD biomarkers; a T-ALL study highlighted markers including CD38, CD99, and TRBC1.
Novartis introduced new long-term social impact and sustainability targets covering access, global health, emissions, waste and water. The plan includes a 2030 access goal and net-zero across the value chain by 2040.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07710781 |
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies |
NOT_YET_RECRUITING | NA |
| NCT07681258 |
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region |
NOT_YET_RECRUITING | |
| NCT07640750 |
Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines |
NOT_YET_RECRUITING | |
| NCT07269470 |
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase |
RECRUITING | PHASE2 |
| NCT07254793 |
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT |
NOT_YET_RECRUITING | PHASE1 |
| NCT06236724 |
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. |
RECRUITING | PHASE2 |
| NCT05800210 |
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases |
RECRUITING | PHASE2 |
| NCT05400122 |
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer |
SUSPENDED | PHASE1 |
| NCT05362773 |
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05334069 |
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection |
RECRUITING |
